PHG Needs Assessment Calculator Ukraine Neural Tube Defects

Welcome to the PHG Health Needs Assessment Calculator for Neural Tube Defects. The contents of this file are listed below.

Full name of the sheet	Short name
Country demographic, maternal health and socioeconomic indicators	Demography
Country health service data	HealthServices
NTD Epidemiology 1.1: Country epidemiology	NTD-E1.1
NTD Epidemiology 1.2: International comparison	NTD-E1.2
NTD Epidemiology 2.1: Data on affected pregnancies: Research studies	NTD-E2.1
NTD Epidemiology 2.2: Data on affected pregnancies: Surveillance	NTD-E2.2
NTD Epidemiology 2.3: Data on affected pregnancies: Other sources	NTD-E2.3
NTD Epidemiology 2.4: Summary of affected pregnancies	NTD-E2.4
NTD Epidemiology 2.5: Sub-population variation in affected pregnancies	NTD-E2.5
NTD Epidemiology 3.1: Mortality data: Research studies	NTD-E3.1
NTD Epidemiology 3.2: Mortality data: Vital registration data	NTD-E3.2
NTD Epidemiology 3.3: Mortality data: Other sources	NTD-E3.3
NTD Epidemiology 3.4: Summary mortality estimates	NTD-E3.4
NTD Epidemiology 3.5: Sub-population variation in mortality	NTD-E3.5
NTD Epidemiology 4.1: Population prevalence: Research studies	NTD-E4.1
NTD Epidemiology 4.2: Population prevalence: Other sources	NTD-E4.2
NTD Epidemiology 4.3: Summary of population prevalence	NTD-E4.3
NTD Epidemiology 4.4: Sub-population prevalence variation	NTD-E4.4
NTD Interventions 1: Effect of folic acid fortification	NTD-Interv1
NTD Interventions 2: Effect of folic acid supplementation	NTD-Interv2
NTD Interventions 3: Effects of prenatal screening and pregnancy termination	NTD-Interv3
NTD Interventions 4: Combined effects of folic acid interventions and prenatal screening	NTD-Interv4
NTD Needs Assessment Calculator 1: Quantitative baseline	NTD-NA1
NTD Needs Assessment Calculator 3: Quantitative assessment of interventions	NTD-NA3
NTD Needs Assessment Appendix: Regression estimating effect of folate fortification	NTD-Appx

(There is no sheet NTD-NA2.)

Note: The Calculator sheets already contain modelled estimates from the PHGDB; note that these estimates do not include NTD associated with chromosomal disorders and other structural malformations.

Ukraine Shared Data

PHG FOUNDATION

Demographic, maternal health and socio-economic indicators

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Demography information from that Calculator into here. The information should be the same.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Number of persons by age-group and sex		Estimates		Yo	our estimat	es	Cho	sen estim	ates
Age group	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4 years	1168468	1104007	2272475			0			0
5-9 years	989902	935327	1925229			0			0
10-14 years	1166792	1111692	2278484			0			0
15-19 years	1551406	1477008	3028414			0			0
20-24 years	1940203	1861291	3801494			0			0
25-29 years	1839257	1787330	3626587			0			0
30-34 years	1664605	1684015	3348620			0			0
35-39 years	1566857	1631966	3198823			0			0
40-44 years	1476471	1605033	3081504			0			0
45-49 years	1674495	1914215	3588710			0			0
50-54 years	1518806	1847240	3366046			0			0
55-59 years	1335537	1739079	3074616			0			0
60-64 years	842366	1212615	2054981			0			0
65+ years	2449767	4867609	7317376			0			0
Total	21184932	24778427	45963359	0	0	0	0	0	0
Female population aged 15-44 years		10046643			-			-	
Data year		2009 reported in 2009							
Source, Year		·	UN 2011						

Ethnicity. Please enter data for the main ethnic groups if you are working with a population that is different from that of the country.

Ethnic group	Number	% population

Crude birth rate Fieve is remained (DB) rt glister / 1000	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
population	12.76	Unicef, 2013				
Still birth rate (SB): Still births (SB) / year / 1000 total births	8.30	WHO, 2009				
Total births in 1000s (LB+SB) per year	494	Unicef, 2013				
Infant mortality rate: infant deaths / 1000 LB / year	8.7	Unicef, 2013				
Under-5 mortality rate: U5 deaths / 1000 LB / year	10.1	Unicef, 2013				
Percentage births in women >35 years						
Life expectancy at birth (yrs)	68.49	Unicef, 2013				
% of marriages consanguineous						

Mataural Israelik	Estimate	Source, Year	Your	Source,	Chosen	Source,
Maternal health			estimate	Year	estimate	Year
Prenatal visits – at least 1 visit (%)	98.5	Unicef, 2013				
Prenatal visits – at least 4 visits (%)	74.8	Unicef, 2013				
Births attended by skilled health personnel (%)	98.7	Unicef, 2013				
Contraception prevalence rate (%)	66.7	Unicef, 2013				
Unmet need for family planning (%)	10.3	WHO, 2007				
Total fertility rate	1.47	Unicef, 2013				
% home births						
% births at health care services	99.00	Unicef, 2013				
Number of neonata <b>Newbกเกลเชอไร่</b> าby SBA / trained	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
staff						
% neonatal examinations by SBA/ trained staff						

Socio-economic indicators	Estimate	Source, Year	Your estimate	,	Source, Year
Gross national income per capita (PPP int. \$)	7080	Unicef, 2013			
% population living on < US\$1 per day	<2.0	Unicef, 2013			
Birth registration coverage (%)	99.8	WHO 2005			
Death registration coverage (%)	90-100	WHO, 2008			

LB = live births
PPP = purchasing power parity
SBA = skilled birth attendant

Ukraine Shared Data Health Services Data

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Health Services information from that Calculator into here. The information should be the same.

This section provides health-service-related information for your country.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Health Expanditure	Estimate	Source, Year	Your estimate	Source,	Chosen	Source,
Health Expenditure	Estimate	rear	estimate	Year	estimate	Year
Per capita total expenditure on health (PPP int. \$)	527.5	WHO 2011				
Total expenditure on health as percentage of GDP	7.2	WHO 2011				
Per capita government expenditure on health (PPP int. \$)	272.7	WHO 2011				
External resources for health as percentage of total expenditure on health	4.2	WHO 2011				
General government expenditure on health as percentage of total expenditure on health	51.7	WHO 2011				
Out-of-pocket expenditure as percentage of private expenditure on health	93.5	WHO 2011				
Private expenditure on health as percentage of total expenditure on health	48.3	WHO 2011				
General government expenditure on health as percentage of total government expenditure	11.7	WHO 2011				

		Source,	Your	Source,	Chosen	Source,
Health Workforce	Estimate	Year	estimate	Year	estimate	Year
Number of nursing and midwifery personnel	388444	WHO, 2006				
Nursing and midwifery personnel density (per 10,000 population)	84.5	WHO, 2006				
Number of physicians	143728	WHO, 2006				
Physician density (per 10,000 population)	31.254	WHO, 2006				
Number of obstetricians						
Number of paediatricians						
Number of paediatric surgeons						
Number of paediatric cardiac surgeons						
Number of paediatric neurosurgeons						
Number of clinical geneticists						
Number of genetic counsellors						
Number of community health workers						
Number of skilled birth attendants (SBA)						
Density of SBA						
Number of lab staff providing cytogenetic testing						

Number of lab staff providing molecular genetics			
Number of lab staff providing biochemical tests for genetics			
Number of skilled health attendants			

		Source,	Your	Source,	Chosen	Source,
Infrastructure	Estimate	Year	estimate	Year	estimate	Year
Number of maternity units						
Number of services providing specialised care for people with CD						
Number of family planning services						
Number of preconception services						
Number of services providing prenatal care						
Number of services providing newborn care						
Number of facilities providing genetic services						
Number of laboratories providing cytogenetics						
Number of laboratories providing molecular genetics						
Number of laboratories providing biochemical tests for genetics						
Number of facillities for safe terminations of pregnancies for fetal defects						

PPP = purchasing power parity GDP = gross domestic product SBA = skilled birth attendant CD = congenital disorders

Ukraine
Neural Tube Defects
NTD Epidemiology 1.1: Country epidemiology

Epidemiological indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Year of estimate						
Prevalence at birth and by age-group (/1000	0)					
Live birth prevalence (LB)			0.50			
Stillbirth prevalence (SB)			0.13			
Total birth prevalence (LB+SB)			0.63			
All age groups						
<1 year olds						
1-4 year olds						
5-14 year olds						
15-44 year olds						
45+ year olds						
Number of cases by age group						
Annual live births			242			
All age groups						
<1 year olds						
1-4 year olds						
5-14 year olds						
15-44 year olds						
45+ year olds						
No. of cases by level of impairment						
No or minor disability						
Moderate disability						
Severe disability*						
Mortality and morbidity						
Mean life expectancy (yrs)			28.8			
No. deaths < 1yr			112			
No. deaths 1-4 yrs			68			
No. deaths < 5 yrs			180			
Infant mortality / 1000 LB			0.23			
Under-5 mortality / 1000 LB			0.37			
Years of life lost LB = live births; SB = stillbirths * Severe di	sability is define	d as: whe	elchair dependence, i	needing help w	ith transfers	,

LB = live births; SB = stillbirths \* Severe disability is defined as: wheelchair dependence, needing help with transfers, continence care and daily living, mostly low IQ, kyphosis, pressure sores, epilepsy and visual defects (a few blind) (Oakeshott and Hunt 2003)

Ukraine Neural Tube Defects NTD Epidemiology 1.2: International comparison

	Your chosen			
Epidemiological indicator	estimates	Country	Region	World
Prevalence at birth and by age-group (/1000 p	eople)		(Europe, Eastern)	
Live birth prevalence (LB)		0.50	0.38	1.38
Stillbirth prevalence (SB)		0.13	0.10	0.54
Total birth prevalence (LB+SB)		0.63	0.48	1.92
All age groups				
<1 year olds				
1-4 year olds				
5-14 year olds				
15-44 year olds				
45+ year olds				
Number of cases by age-group				
Annual live births		242	889	184,465
All age groups				
<1 year olds				
1-4 year olds				
5-14 year olds				
15-44 year olds				
45+ year olds				
No. cases by level of impairment				
No or minor disability				
Moderate disability				
Severe disability*				
Mortality and morbidity				
Mean life expectancy (yrs)		28.8	32.7	10.9
No. deaths < 1yr		112	379	156,571
No. deaths 1-4 yrs		68	268	11,826
No. deaths < 5 yrs		180	646	168,397
Infant mortality / 1000 LB		0.23	0.43	0.85
Under-5 mortality / 1000 LB		0.37	0.73	0.91
Years of life lost				

LB = live births \* Severe disability is defined as: wheelchair dependence, needing help with transfers, continence care and daily living, mostly low IQ, kyphosis, pressure sores, epilepsy and visual defects (a few blind) (Oakeshott and Hunt 2003)

**Neural Tube Defects** 

NTD Epidemiology 2.1: Data on affected pregnancies: Research studies

Study author, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies listed above (or in section NTD-E2.1 of the Tool), enter the best estimates for the prevalence of affected births and terminations in the country, and a range of values to reflect uncertainty or within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	LB prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			
Estimates for the total country/territory	Number of affected stillbirths	SB prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			
Estimates for the total country/territory	Number of terminations of pregnancy due to condition	ToP / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

NTD Epidemiology 2.2: Data on affected pregnancies: Surveillance

Based on surveillance data, enter the best estimates for the prevalence of the condition in live births, stillbirths and pregnancy terminations in the country. Give a range of values to reflect uncertainty and within-country variation, and use comments for information on data quality, uncertainty and representativeness.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	Birth prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

Estimates for the total country/territory	Number of affected stillbirths	Stillbirth prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

Estimates for the total country/territory	Number of ToP due to condition	ToP / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

NTD Epidemiology 2.3: Data on affected pregnancies: Other sources

	Source 1:	Source 2:		Notes
Enter year and source of data – use last year with information available.				
Basic Numbers				
Number of affected live births / year, from data source				
Total number of live births / year, from data source				
Number of affected still births / year, from data source				
Total number of stillbirths / year, from data source				
Number of ToP for affected fetus / year from data source				
Total number of affected births / year (live and still)		0	0	
Total number of births / year, from data source		0	0	
Total number of ToP / year, from data source				
Total number of women aged 15-44				
Live birth prevalence: recorded and estimated				
Recorded live birth prevalence	#D	IV/0!	#DIV/0!	
(affected recorded live births / 1000 recorded total births)				
Estimated completeness of recording: what proportion of true affected live births in your				Range: 0 to 1
data source were recorded?				italige. 0 to 1
Estimated coverage of recorded live births (number of recorded live births / total live births				Range: 0 to 1
in country or territory)				range: 0 to 1
Estimated live birth prevalence (recorded prevalence / completeness)	#D	IV/0!	#DIV/0!	
Estimated true number of affected live births in data source (number of recorded affected	#D	IV/0!	#DIV/0!	
live births / completeness)		N // 0 1	//D D //O1	
Estimated number of affected live births in total population (number of affected live births	#D	IV/0!	#DIV/0!	
from data source / (coverage x completeness))				
Stillbirth prevalence: recorded and estimated	40	1) // 0.1	#DI\//01	
Recorded stillbirth prevalence (affected recorded still births / 1000 recorded total births)		IV/0!	#DIV/0!	
Estimated completeness of recording: what proportion of true affected stillbirths in your data source were recorded?				Range: 0 to 1
Estimated coverage of recorded stillbirths				Range: 0 to 1
(number of recorded still births / total still births in country or territory)				italige. V to 1
Estimated stillbirth prevalence	#D	IV/0!	#DIV/0!	
(recorded prevalence / completeness)				
Estimated true number of affected stillbirths in data source (number of recorded affected still births / completeness)	#D	IV/0!	#DIV/0!	

Estimated number of affected stillbirths in total population (number of affected still births	#DIV/0!	#DIV/0!
from data source / (coverage x completeness))		

ToP prevalence: recorded and estimated			
Recorded ToP prevalence (ToP in affected fetuses / 1000 women aged 15-44)	#DIV/0!	#DIV/0!	
Estimated completeness of recording: what proportion of true affected pregnancy terminations in your data source were recorded?			Range: 0 to
Estimated coverage of recorded ToP (number of recorded ToP / total ToP in country or territory)			Range: 0 to
Estimated ToP prevalence (recorded prevalence / estimated completeness)	#DIV/0!	#DIV/0!	
Estimated true number of ToP in data source (number of recorded ToP / completeness)	#DIV/0!	#DIV/0!	
Estimated number of ToP in total population (number of ToP from data source / (coverage x completeness))	#DIV/0!	#DIV/0!	

Based on the sources above, enter the best prevalence estimates for your population, and a range of values to reflect uncertainty of estimates and within country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the whole country/territory	Number of affected live births	LB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		
Estimates for the whole country/territory	Number of affected still births	SB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		
Estimates for the whole country/territory	Number of ToP due to condition	ToP /1000 TB
Best estimate		
Lower estimate		
Higher estimate		

Ukraine Neural Tube Defects NTD Epidemiology 2.4: Summary of affected pregnancies

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Number of annual affected live births	3		242			
Annual birth prevalence / 1000 TB			0.50			
Number of annual affected still births	\$		62			
Stillbirth prevalence / 1000 TB/year			0.13			
Number of terminations of pregnancy in affected fetuses /year						
Affected ToP / 1000 TB						

If there are specific sub-types of condition, you can repeat this exercise below. However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

Ukraine
Neural Tube Defects
NTD Epidemiology 2.5: Sub-population variation in affected pregnancies

If the birth prevalence rates vary by population sub-group (e.g. geographically or by another factor), indicate any population groups with different prevalence estimates from the whole population and describe reasons for variation. If a group is substantially different from the general population, you may wish to conduct a needs assessment for that

Population sub- group	Number of affected live births	LB prevalence / 1000 TB	Reason for variation

Population sub- group	Number of affected stillbirths	SB prevalence / 1000 TB	Reason for variation

Number of ToP in affected pregnancies	ToP prevalence / 1000 TB	Reason for variation

NTD Epidemiology 3.1: Mortality data: Research studies

Source, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies above, enter the best estimates for the specific mortality by age-group e.g. infant, under-5s, etc., as appropriate, and a range of values to reflect uncertainty of estimates and within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Mortality estimates	Number of deaths	Ratio (deaths / 1000 LB)	Comments
Neonatal group (<28 days)			
Best estimate			
Lower estimate			
Higher estimate			
Infant group (<1 year)			
Best estimate			
Lower estimate			
Higher estimate			
Under-5 group (<5 years)			
Best estimate			
Lower estimate			
Higher estimate			
Other age group:			
Best estimate			
Lower estimate			
Higher estimate			

LB = live births

NTD Epidemiology 3.2: Mortality data: Vital registration data

Fill in the blank cells based on your vital registration data.	
Enter year and source of data	
Registered data	
Total registered live births	
Registered condition-specific neonatal deaths (first 28 days of life)	
Registered condition-specific infant deaths (first year of life)	
Registered condition-specific under-5 deaths (first 5 years of life)	
Registered condition-specific neonatal mortality ratio (condition-specific neonatal deaths / 1000 live births in the same year)	#DIV/0!
Registered condition-specific infant mortality (condition-specific infant deaths / 1000 live births in the	#DIV/0!
Registered condition-specific under-5 mortality (condition-specific under-5 deaths / 1000 live births in the same year)	#DIV/0!

Adjustment for under-ascertainment of cause of death and sub-registration of deaths: Enter estimates in the highlighted cells. It is not always possible to adjust the estimates, in which case you may give the value '1', accepting that the estimates in these cases will usually be biased towards low values. (Or you may move to the next section.)

It is assumed that under-ascertainment is stable across age-groups; if ascertainment varies by age-group, you could use separate estimates for each age group.

· · · · · · · · · · · · · · · · · · ·		
Estimated completeness of recording: what proportion of deaths in affected persons were registered as		Range: 0 to 1
թեթանույթ coverage: what proportion of the total country/territory population is covered by the vital		Range: 0 to 1
Delitiration coverage x completeness)	0	
Estimated values for the total country/ territory population		
Estimated number of live births in total population	#DIV/0!	
Estimated number of neonatal deaths in total population (number of deaths registered in neonatal period / ascertainment)	#DIV/0!	
Estimated number of infant deaths in total population (number of deaths registered in first year of life / ascertainment)	#DIV/0!	
Estimated number of under-5 deaths in total population (number of deaths registered in under-5s / ascertainment)	#DIV/0!	
Estimated neonatal mortality ratio (estimated neonatal deaths / 1000 live births)	#DIV/0!	
Estimated infant mortality ratio (estimated infant deaths / 1000 live births)	#DIV/0!	
Estimated under-5 mortality ratio (estimated under-5 deaths / 1000 live births)	#DIV/0!	

NTD Epidemiology 3.3: Mortality data: Other sources

Source, year, site	Sample size	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Neonatal mortality		Infant mortality		Under-5 mortalit	у
Estimates for the total	Value	Ratio/1000 LB	Value	Ratio/1000 LB	Value	Ratio/1000 LB
country/territory						
Best estimate						
Lower estimate						
Higher estimate						

Ukraine Neural Tube Defects NTD Epidemiology 3.4: Summary mortality estimates

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Year of data collection						
Number of annual deaths in affected persons						
Number of annual live births (in 1000s)			482			
Number of annual affected neonatal deaths			96			
Number of affected neonatal deaths / 1000 LB			0.20			
Number of annual affected infant deaths			112			
Number of affected infant deaths / 1000 LB			0.23			
Number of annual affected under-5 deaths			180			
Number of affected under-5 deaths / 1000 LB			0.37			
Mean life expectancy at birth in affected			28.8			
Dtnordurators (e.g. survival following surgical procedure, etc)						

Ukraine
Neural Tube Defects
NTD Epidemiology 3.5: Sub-population variation in mortality

Age group: neonatal Population sub-group	Cause-specific, group-specific neonatal mortality ratio / 1000 LB	Reason for variation

Age group: infant Population sub-group	Cause-specific, group-specific infant mortality ratio / 1000 LB	Reason for variation

			Reason for variation
Population sub-group	affected persons	under-5 mortality ratio / 1000 LB	

Age group:		, , , , , , , , , , , , , , , , , , , ,	Reason for variation
Population sub-group	affected persons	mortality ratio / 1000 population	

NTD Epidemiology 4.1: Population prevalence: Research studies

Study, year, site	Study quality and representativeness	Main findings

Based on the studies above, enter the best estimates for population prevalence, and a range of values to reflect uncertainty of estimates and within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

NTD Epidemiology 4.2: Population prevalence: Other sources

Source, year, site	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

NTD Epidemiology 4.3: Summary of population prevalence

Source of estimates	Estimated total population number of affected persons	Range	Estimated total population prevalence / 1000 persons	Range
1				
2				
3				
4				
5				
PHGDB				
Chosen estimates				

Ukraine
Neural Tube Defects
NTD Epidemiology 4.4: Sub-population prevalence variation

Population sub-group	Number of affected people	Total number of people in population sub-group	Population prevalence per 1000 people	Reason for variation
			#DIV/0!	

If there are specific sub-types of condition, you can repeat this exercise (copy table and paste below). However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

Formula in column D: Number of affected people/ (Total number of people in population subgroup/1000)

**Neural Tube Defects** 

NTD Interventions 1: Effect of folic acid fortification

This sheet allows you to estimate the potential reduction in NTD prevalence through fortification of food with folic acid. Please start by entering values reflecting your current situation. If you have no fortification programme, enter 0 for coveraç Below, you may adjust dosage and coverage levels to demonstrate the effects of different intervention scenarios.

Current situation		Notes
Present estimated NTD prevalence per 1000 TB		
Present dosage (ppm)		Range: 1.5 to 3
Present coverage of fortification Baseline NTD prevalence per 1000 TB, with no folic acid fortification*		Range: 0 to 1
TOTUTGATION		
Minimum prevalence NTD / 1000 births	0.9	This value is fixed at 0.9

Potential scenarios, based on your present situation	
Vary dosage (ppm)	Range: 1.5 to 3
Vary proportional population coverage	Range: 0 to 1
Estimated NTD prevalence with this scenario, per 1000 TB	<- Do not modify this cell!
Absolute prevalence reduction with this scenario, per 1000 TB	<- Do not modify this cell!

ppm = parts per million

TB = total births (live births + stillbirths)

Formula in B13:IF(B10="";"";IF(((B10-(1.07\*B12)+(0.15\*B11\*B12))/(1-0.88\*B12))<B15;B15;((B10-(1.07\*B12)+(0.15\*B11\*B12))/(1-0.88\*B12)))) Formula in B20: IF(B13=""; ""; IF(B13=0.9;0.9;IF((1.07\*B19+0.12\*B13\*B19-0.15\*(IF(B18="";B11;B18))\*B19+B13-B13\*B19)<B15;B15;(1.07\*B19+0.12\*B13\*B19-0.15\*(IF(B18="";B11;B18))\*B19+B13-B13\*B19)))) Formula in B21:IF(B20="";"";B13-B20)

See sheet NTD-Appx for explanation of regression.

<sup>\*</sup> Not considering the effects of other interventions on prevalence.

**Neural Tube Defects** 

NTD Interventions 2: Effect of folic acid supplementation

This sheet allows you to estimate the potential reduction in NTD incidence through folic acid supplementation for pregnant women.

Please enter a value for population coverage of folic acid supplementation, to determine its potential effect.

Effect of supplementation (with no fortification)		Notes
Baseline prevalence with no folic acid intervention		This can be taken from the appropriate cell (baseline NTD prevalence)
(per 1000 TB)		in sheet NTD-Interv1.
Maximum proportional reduction (assuming 100%		
coverage)	0.72	This value is fixed at 0.72
Population supplementation coverage		Range: 0 to 1
Actual proportional reduction	0	Maximum proportional reduction x Coverage
Actual prevalence reduction (per 1000 TB)	0.000	Baseline incidence x Actual proportional reduction
Minimum prevalence	0.9	This value is fixed at 0.9
		Baseline prevalence-((Maximum proportional reduction X Population
New prevalence		supplementation coverage) x Baseline prevalence)
New prevalence	0.000	Supplementation coverage, x baseline prevalence,
% prevalence reduction	#DIV/0!	1 – (New prevalence/Baseline prevalence)
Absolute prevalence reduction (per 1000 TB)	0.000	Baseline prevalence- New prevalence
Final prevalence following supplementation	0.900	Cannot go below 0.9 / 1000 LB

Now you can see below the potential combined effect of folate fortification and supplementation:

Additional effect of supplementation, given fortification		This value can be changed.
	New prevalence	
After fortification		This value set in sheet NTD-Interv1
After supplementation		
After fortification and supplementation	0.000	Requires input in blank cells above <sup>1</sup>
% reduction	#DIV/0!	Requires input in blank cells above <sup>2</sup>
Final prevalence after fortification and supplementation		

TB = total births (live births + stillbirths)

<sup>1</sup>New Prevalence after fortification-(Additional effect of supplementation x Final prev. following supplemen.)

<sup>2</sup>If New prevalence after fortification < minimum prevalence then use (Baseline prev – min prevalence)/baseline prevalence)

Otherwise use: (Baseline prevalence - new prevalence after fortification and supplementation)/baseline prevalence

**Neural Tube Defects** 

NTD Interventions 3: Effect of prenatal screening and pregnancy termination

Assumption: prenatal services are equally used for cases which would lead to still births and live births.

This could overestimate the impact of ToP if in fact ToP is more likely for severe cases that would result in stillbirth.

Conversely, the impact of ToP could be underestimated if screening is only available to high-income women at lower risk.

100% specificity of prenatal diagnosis assumed.

Baseline prevalence, per 1000 TB (LB + SB)		See previous two sheets. Use baseline either before or after folic acid interventions.
Variables		
Coverage of prenatal screening		Range: 0 to 1
Proportion of screen-positive cases receiving diagnosis		Range: 0 to 1
Proportion of diagnosed cases ending in pregnancy termination		Range: 0 to 1
Results		
% prevalence reduction due to PND & pregnancy termination <sup>1</sup>	0%	
Prevalence reduction due to PND & pregnancy termination, per 1000 TB <sup>2</sup>	0.000	
Final birth prevalence of NTDs after PND & pregnancy termination, per 1000 TB <sup>3</sup>	0.000	

PNS = prenatal screening

**ToP = termination of pregnancy** 

TB = total births (live births + still births)

<sup>1</sup>Coverage of screening X Proportion of screen-positive cases receiving diagnosis x Proportion of cases ending in pregnancy termination

<sup>&</sup>lt;sup>2</sup>% prevalence reduction due to PND and termination x Baseline prevalence

<sup>&</sup>lt;sup>3</sup>Baseline prevalence - Prevalence reduction due to PND & termination

**Neural Tube Defects** 

NTD Interventions 4: Combined effects of folic acid interventions and prenatal screening

This sheet will only work if the previous three sheets (NTD-Interv1, 2 3) have been completed.

Variables		Notes
Baseline prevalence (per 1000 TB)		See e.g. Baseline prior to FA interventions in sheet NTD-Interv1
Prevalence reduction through FA interventions (per 1000 TB)	0.000	Set in sheet NTD-Interv2
% prevalence reduction after folic acid <sup>1</sup>	#VALUE!	
Coverage of prenatal diagnosis	0	Set in sheet NTD-Interv3
Prevalence of pregnancy termination in confirmed cases	0	Set in sheet NTD-Interv3
Prevalence reduction through PNS	0.000	Set in sheet NTD-Interv3
% prevalence reduction due to PNS <sup>2</sup>	0%	
Final prevalence after folic acid and PNS (per 1000 TB) <sup>3</sup>	0.000	
Combined prevalence reduction (per 1000 TB)⁴	0.000	
Combined % prevalence reduction <sup>5</sup>	#VALUE!	

PNS = prenatal screening

TB = total births (live births + stillbirths)

FA = folic acid

<sup>&</sup>lt;sup>1</sup> Prevalence reduction through FA interventions/Baseline prevalence

<sup>&</sup>lt;sup>2</sup> Coverage of prenatal diagnosis x Prevalence of pregnancy termination of confirmed cases

<sup>&</sup>lt;sup>3</sup> Baseline prevalence = Prevalence reduction through FA interventions – Prevalence reduction through PNS

<sup>&</sup>lt;sup>4</sup> Baseline prevalence – Final prevalence after folic acid and PNS

<sup>&</sup>lt;sup>5</sup> 1- (Final prevalence after folic acid and PNS/Baseline prevalence)

NTD Needs Assessment Calculator 1: Quantitative baseline

Table NTD-NA1a Burden of Neural Tube Defects in pregnancy, at birth and at population level

		Chosen estimates			
Indicator	Number (n)	n/1000 TB	Range of prevalence (/1000 TB)		
Annual affected live births (LB)	0	0	0	Drawn from sheet E2.4	
Annual affected stillbirths (SB)	0	0	0	Drawn from sheet E2.4	
Annual affected births (LB+SB)	0	0		Drawn from sheet E2.4	
Annual affected persons (all age	0	0	0	Drawn from sheet E1.1	
groups)			-		

Table NTD-NA1b Neural Tube Defects mortality indicators

		Notes		
Indicator	Number (n)	I .	Range of prevalence (/1000 TB)	
Annual overall mortality	0			Drawn from sheet E3.4
Annual neonatal mortality	0	0	0	Drawn from sheet E3.4
Annual infant mortality	0	0	0	Drawn from sheet E3.4
Annual under-5 mortality	0	0	0	Drawn from sheet E3.4
Mean life expectancy at birth among affected people	0		0	Drawn from sheet E3.4

TB = total births (live births + stillbirths)

NTD Needs Assessment Calculator 3: Quantitative assessment of interventions

Table NTD-NA3a	Estimated prevalence in the absence of interventions for Neural Tube Defects			
Indicator	Number (n) Prevalence (n/1000)			
Potential live births				
Potential still births				

Table NTD-NA3b	Current situation in relation to interventions before birth				
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 TB		
Effect of family planning, education					
Effect of folic acid fortification					
Effect of folic acid supplementation	ĺ				
Effect of prenatal diagnosis					
Overall effect					

Table NTD-NA3c	Target situation in relation to interventions before birth				
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 TB		
Effect of family planning, education	n				
Effect of folic acid fortification					
Effect of folic acid supplementation	n				
Effect of prenatal diagnosis					
Overall effect					

Table NTD-NA3d	Current situation in relation to interventions after birth				
Intervention	Coverage (%)	Cases managed (n)	Cases managed/1000 TB		
Effect of newborn diagnosis					
Effect of surgical treatment					
Effect of social care and support					
Effect of rehabilitation					
Overall effect					

Table NTD-NA3e	Target situation in relation to interventions after birth					
Intervention	Coverage (%) Cases managed (n) Cases managed/1000					
Effect of newborn diagnosis						
Effect of surgical treatment						
Effect of social care and support						
Effect of rehabilitation						
Overall effect						

Table NTD-NA3f	Current and desired out	comes			
	Current situation	Current situation T		Target situation	
Indicator	Annual number (n) Prevalence (n/1000)		Annual number (n)	Prevalence (n/1000)	
Estimated affected pregnancies					
Live births (LB)	0	0			
Stillbirths (SB)	0	0			
Total births (LB+SB)	0	0			
Estimated population prevalence					
All age groups					
Estimated mortality / 1000 live birth	S				
Neonatal deaths	0	0			
Infant deaths	0	0			
Under-5 deaths	0	0			

TB = total births (live births + stillbirths)

**Neural Tube Defects** 

NTD Needs assessment appendix: Regression estimating effect of folic acid fortification

Data from Wald et al.<sup>1</sup> was used to create a regression. The following output, adapted from Stata, gives the basis for the formula used in cell B13 of sheet NTD-Interv1. Due to the use of a limited data set, the regression is accurate within a limited range.

regress incid baseline ppm

Output	
- Carput	

Source	SS	df	MS	Number of obs = 12
Model	0.282	2	0.141	Prob > F = 0.0164
Residual	0.188	9	0.021	R-squared = 0.5991
				Adj R-squared = 0.5100
Total	0.470	11	0.043	Root MSE = .14468

incid	Coef.	Std. Err.	t	P> t	95% Conf.	Interval
baseline	0.121	0.071	1.69	0.12	-0.041	0.283
ppm	-0.154	0.047	3.25	0.010	-0.261	-0.047
_cons	1.072	0.164	6.52	0.000	0.700	1.444

Prevalence = (0.12 x baseline prevalence) - (0.15 x ppm) + 1.07

<sup>1</sup>Wald NJ, Law MR, Morris JK, Wald DS. 2001.Quantifying the effect of folic acid. Lancet 358:2069-73.